

Original article

The impact of education inequality on rheumatoid arthritis risk is mediated by smoking and body mass index: Mendelian randomization study

Sizheng Steven Zhao ^{1,2}, Michael V. Holmes³, Jie Zheng², Eleanor Sanderson^{2,4} and Alice R. Carter^{2,4}

Abstract

Objective. To estimate the causal relationship between educational attainment—as a proxy for socioeconomic inequality—and risk of RA, and quantify the roles of smoking and BMI as potential mediators.

Methods. Using the largest genome-wide association studies (GWAS), we performed a two-sample Mendelian randomization (MR) study of genetically predicted educational attainment (instrumented using 1265 variants from 766 345 individuals) and RA (14 361 cases, 43 923 controls). We used two-step MR to quantify the proportion of education's effect on RA mediated by smoking exposure (as a composite index capturing duration, heaviness and cessation, using 124 variants from 462 690 individuals) and BMI (517 variants, 681 275 individuals), and multivariable MR to estimate proportion mediated by both factors combined.

Results. Each s.d. increase in educational attainment (4.2 years of schooling) was protective of RA (odds ratio 0.37; 95% CI: 0.31, 0.44). Higher educational attainment was also protective for smoking exposure ($\beta = -0.25$ s.d.; 95% CI: -0.26 , -0.23) and BMI [$\beta = -0.27$ s.d. (~ 1.3 kg/m²); 95% CI: -0.31 , -0.24]. Smoking mediated 24% (95% CI: 13%, 35%) and BMI 17% (95% CI: 11%, 23%) of the total effect of education on RA. Combined, the two risk factors explained 47% (95% CI: 11%, 82%) of the total effect.

Conclusion. Higher educational attainment has a protective effect on RA risk. Interventions to reduce smoking and excess adiposity at a population level may reduce this risk, but a large proportion of education's effect on RA remains unexplained. Further research into other risk factors that act as potentially modifiable mediators are required.

Key words: education, Mendelian randomization, rheumatoid arthritis, mediation, smoking, body mass index

Rheumatology key messages

- Genetically predicted higher educational attainment—as a proxy for socioeconomic position—is protective for RA.
- Twenty-four per cent of this effect was mediated by smoking behaviour and 17% by body mass index.
- Efforts to reduce smoking and excess adiposity would help mitigate against socioeconomic inequalities in RA.

Introduction

Socioeconomic deprivation is recognized to be associated with increased risk of RA [1], but observational associations may have limited causal interpretation.

Indices of local deprivation correlate poorly with individual socioeconomic position and are prone to ecological fallacy, while individual-level proxies such as income are often subject to reporting bias [2]. Furthermore, the causal direction is often difficult to establish; occupation, income and even area of residence (used to derive local deprivation indices) can each be influenced by work disability that can follow RA [3]. By contrast, educational attainment is largely determined in early life (predating, thus less likely influenced by, RA) and less likely to change over time (unlike income or occupation). Education is strongly correlated with employment, income and other later life measures of socioeconomic position, thus serves as a good proxy [4].

¹Musculoskeletal Biology, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, ²MRC Integrative Epidemiology Unit, University of Bristol, Bristol, ³MRC Population Health Research Unit at the University of Oxford, Oxford and ⁴Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

Submitted 15 April 2021; accepted 10 August 2021

Correspondence to: Alice R Carter, MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
E-mail: alice.carter@bristol.ac.uk

The mechanism through which higher educational attainment protects against RA is not known; there have been no studies of causal intermediates, or mediators, to our knowledge. Education is intimately associated with smoking [5] and adiposity (e.g. measured using BMI) [6], but whether and to what extent these established risk factors explain the total effect of education on RA has not been investigated. Understanding the population-level implications of changes to smoking behaviour and BMI are important for reducing the effect of educational inequality on RA risk. Quantifying the proportion of the total effect unaccounted for may additionally highlight the need to study as yet undescribed intermediate factors. Such mediators may be more amenable to intervention, whereas efforts to improve educational opportunities across the population require intervention in early life and are beyond the scope of most clinical practices.

Mendelian randomization (MR) mediation analysis can be used to address these unmet research needs. MR is an observational study design that uses genetic variants as instrumental variables to estimate the causal effect of the exposure on the outcome (a brief overview including interpretation can be found in [7, 8]). Since variants are randomly allocated at conception, MR is less susceptible to confounding, measurement error and reverse causation than many other observational designs. These strengths also apply to mediation analysis; for example, mediation analysis requires no unmeasured confounding between any of the exposure, mediator and outcome,

which is difficult to achieve in traditional observational approaches [9]. MR can also test reverse causation, e.g. whether RA or smoking influence educational attainment. Using two-sample MR, we aimed to investigate the effect of educational attainment on the risk of RA and quantify the roles of smoking and BMI as mediators.

Methods

GWAS summary data

We obtained summary single nucleotide polymorphism (SNP)–phenotype association data from genome-wide association studies (GWAS) of each respective phenotype (summarized in Table 1). Educational attainment (self-reported at age ≥ 30 years) was derived from the Social Science Genetic Association Consortium GWAS meta-analysis of years of schooling in 766 345 participants of European ancestry [10] (additional details of each cohort are shown in Supplementary Table S1, available at *Rheumatology* online). Each major educational qualification was mapped to the International Standard Classification of Education to derive the equivalent years-of-education. One s.d. represents 4.2 years of additional schooling. BMI data were obtained from the Genetic Investigation of Anthropometric Traits consortium GWAS meta-analysis of 681 275 participants of European descent [11]. One s.d. represents 4.8 kg/m². Smoking was studied as

TABLE 1 Summary of each genome-wide association study

Study	Study population	Sample size	One s.d.	No. of SNPs	r^2	F
Educational attainment [10]	Lee <i>et al.</i> GWAS meta-analysis	766 345	4.2 years	1265	5.9%	44.3
BMI [11]	Yengo <i>et al.</i> GWAS meta-analysis	681 275	4.8 kg/m ²	517	5.3%	73.7
Lifetime smoking exposure ^a [12]	UK Biobank	462 690	For example, smoking 20 cigarettes a day for 15 years and stopping 17 years ago	124	0.5%	41.4
RA ^b [13]	Okada <i>et al.</i> GWAS meta-analysis	58 284	n/a	46	n/a	n/a
Educational attainment [14]	Okbay <i>et al.</i> GWAS	293 723	3.7 years	73	0.9%	38.3
Alcoholic drinks per week [15]	Liu <i>et al.</i> GWAS	335 394	9 additional drinks per week	35	0.6%	96.5
Number of days/week of vigorous physical activity [16]	UK Biobank	440 512	1.95 days	11	0.4%	150
Dietary protein	Meddens <i>et al.</i> GWAS [17]	268 922	102 kcal ^c	7	0.2%	58.2
Dietary fat		268 922	270 kcal ^c	5	0.2%	95.6
Dietary carbohydrate		268 922	334 kcal ^c	12	0.2%	41.2

^aDerived from smoking status (current, former, never), age at initiation in years, age at cessation in years and number of cigarettes smoked per day. ^bUse in reverse MR of RA's effect on education. ^cOne s.d. increase in the context of mean total energy intake of 2064 kcal. Dietary components as percentage of total energy intake measured using the food frequency questionnaire. GWAS: genome-wide association study; n/a: effect allele frequency not available for RA to allow estimation of r^2 and F -statistic; SNP: single nucleotide polymorphism.

'lifetime smoking exposure' in a GWAS of 462 690 participants of European ancestry in the UK Biobank. The mean value of lifetime smoking score was 0.359 (s.d. 0.694). Rather than using binary smoking status, which may present methodological challenges [18], the smoking index takes into account smoking status (current/former/never), and exposure (duration/heaviness/cessation) among ever smokers, i.e. $(1 - 0.5^{\text{smoking-duration/half-life}})(0.5^{\text{time-since-cessation/half-life}})\ln(\text{cigarettes per day} + 1)$. This GWAS has been described in detail [12]. The index ranged from 0.007 (1 cigarette per day for 1 year) to 4.169 (currently smoking 140 a day and starting from age 11); one s.d. increase in the smoking index is equivalent to, for example, an individual smoking 20 cigarettes a day for 15 years and stopping 17 years ago or an individual smoking 60 cigarettes a day for 13 years and stopping 22 years ago [12].

RA genetic associations were obtained from a GWAS meta-analysis of 14 361 RA cases and 43 923 controls [13]. All cases fulfilled the 1987 American College of Rheumatology criteria or were diagnosed with RA by a rheumatologist; 91% were seropositive for anti-CCP antibodies or rheumatoid factor. Additional details of each cohort reported by Okada *et al.* [13] are shown in Supplementary Table S2, available at *Rheumatology* online.

Instrumental variable selection and data harmonization

Genetic instruments for educational attainment were selected as the 1265 independent genome-wide significant ($P < 5 \times 10^{-8}$) SNPs that were not shared with variants instrumenting BMI or smoking. Instruments for BMI and smoking exposure were identified as the lead SNPs reaching genome-wide significance after removing SNPs in linkage disequilibrium ($r^2 < 0.001$ or distance > 10 000 kb) or shared with instruments for education. For all analyses, alleles were aligned to correspond to an increase in educational attainment. All effect alleles were checked to be on the forward strand. Where SNPs were absent in one of the exposure-outcome sets, SNPs in linkage disequilibrium ($r^2 > 0.9$) were used as proxies. We calculated F -statistics for each exposure in univariable MR, and conditional F -statistics in MVMR, with F -statistics > 10 considered suggestive of adequate instrument strength [19]. The F -statistic is derived from the variance explained (R^2) by SNPs for each exposure by $(R^2/K)/[(1-R^2)(N-K-1)]$, where K is the number of SNPs and N the sample size.

Effects of education on RA, smoking exposure and BMI

A graphical summary of analyses is given in Fig. 1. First, we performed univariable two-sample MR to estimate the effect of educational attainment on RA (c in Fig. 1A)—referred to as the total effect—and effect of education on each mediator (a in Fig. 1B). We then used multivariable MR (MVMR) to estimate the effect of each mediator on RA (b in Fig. 1B), adjusting for education.

Decomposing mediated effects

The total effect of an exposure on an outcome can be decomposed into indirect (i.e. effect mediated through a causal intermediate) and direct (i.e. not through the mediator) effects [9]. The total effect of educational attainment on RA risk was decomposed into (i) the direct effect of education on RA after adjusting for each mediator (c' in Fig. 1C), and (ii) the indirect effect of education through each mediator individually. The indirect effect of each mediator was derived using the product method; for example, the indirect effect of education on RA, through smoking, was obtained by multiplying the effect of education on smoking and the effect of smoking on RA ($a \times b$ in Fig. 1B).

To derive the indirect effect by smoking and BMI combined, the difference method was used ($c - c'$), where the direct effect, c' , was the effect of education adjusting for both smoking and BMI in an MVMR model.

For all mediators individually and combined, we quantified the proportion mediated by dividing indirect effect by the total effect. Confidence intervals were estimated using the delta method.


Univariable and multivariable MR methods

We used the inverse-variance weighted method for the main univariable analysis, which combines results from each SNP using multiplicative random-effect meta-analysis [20]. Heterogeneity—a potential indicator of horizontal pleiotropy (and violation of MR assumptions)—was assessed using Cochran's Q -statistic. To test for potential bias from horizontal pleiotropy, we performed a series of sensitivity analyses using the weighted median [21] and mode-based estimators [22], MR-Egger regression [23] and MR-PRESSO (Pleiotropy RESidual Sum and Outlier) [24]. Each method relaxes certain MR assumptions such that a consistent effect across the multiple methods should be more robust against bias from horizontal pleiotropy (summarized in Table 2).

For MVMR, we used the inverse-variance weighted method, with MR-Egger as sensitivity analysis [25]. The pairwise covariance between SNP associations was assumed to be zero in the primary analysis. We tested this assumption using a range of covariance values. Conditional instrument strength was quantified using the modified F -statistic and heterogeneity was assessed using modified Cochran's Q -statistic [25].

Sensitivity analyses

First, we tested for potential mis-specification of the exposure (i.e. whether SNPs influence the exposure first and then the outcome) using Steiger filtering [26]. We also tested potential for reverse causation, that is, using genetic instruments for RA, smoking exposure and BMI to examine their effects on educational attainment; genetic instruments were chosen using the same approach as above. Second, we tested potential bias from overlapping samples [27] (GWAS meta-analyses for education, smoking and BMI all contain UK Biobank

Fig. 1 Diagrams illustrating associations examined in this study

(A) The total effect of educational attainment (EA) on RA, c , was derived using univariable MR (i.e. genetically predicted EA as exposure and RA as outcome). (B) The total effect was decomposed into: (i) indirect effect using a two-step approach (where a is the total effect of EA on smoking, and b is the effect of smoking on RA adjusting for EA) and the product method ($a \times b$) and (ii) direct effect ($c' = c - a \times b$). The same process applied to mediation analysis of BMI. (C) For mediation by both smoking and BMI combined (arrows represent their bidirectional causal relationship), the indirect effect was derived using the difference method ($c - c'$). Proportion mediated was the indirect effect divided by the total effect.

participants) using an earlier GWAS of educational attainment without UK Biobank participants [14]. Third, to address weak conditional instrument strength in MVMR analyses including smoking we: (i) restricted analyses to the 10% most strongly associated SNPs for each exposure where conditional instrument strength was weak (this reduces bias from weak instruments but also reduces precision) and (ii) used the weak instrument robust estimator [28].

Although smoking and BMI are the leading modifiable risk factors for RA, prior studies have also proposed several related lifestyle factors as risk factors [29]. We additionally considered physical activity (number of days per week of vigorous physical activity lasting >10 min) [16], alcohol consumption (drinks per week) [15], and dietary composition (self-reported relative fat, protein, carbohydrate intake) [17] as risk factors for RA. All

analyses were performed in R using the TwoSampleMR and MVMR packages [25, 30].

Results

Genetic instruments for educational attainment explained 5.9% of its variance, with an univariable F -statistic of 38. The variance explained by, and F -statistic for, SNPs instrumenting smoking exposure were 0.5% and 37, and BMI 5.3% and 74.

Effects of education on RA, BMI and smoking behaviour

For each s.d. (4.2 years) increase in educational attainment, the relative odds of RA were 63% lower [odds ratio (OR) 0.37; 95% CI: 0.31, 0.44]. Higher educational

TABLE 2 Summary of each Mendelian randomization method

MR method	Strengths and weaknesses
Inverse-variance weighted	A weighted mean of individual variant effects on the outcome, which provides an estimate equivalent to MR using individual-level data, assuming the genetic variants are uncorrelated. The inverse-variance weighted method has optimal statistical power, but assumes all variants are valid instruments. Estimates are biased if there is directional pleiotropy (when the average value of the pleiotropy distribution is non-zero) [20].
MR-Egger	Quantifies directional pleiotropy and accounts for it to provide an unbiased estimate even if all SNPs have pleiotropic effects. It requires the size of pleiotropic effects to be independent of the size of the variants' effects on the exposure (the InSIDE assumption), which is not verifiable. It is sensitive to outliers and less efficient (results in wide CIs) [23].
Weighted median	Robust to outliers; it provides unbiased estimate when up to half of the SNPs violate the instrumental variable assumptions, but may be less efficient [21].
Mode-based estimation	Robust to outliers; it assumes SNPs in the largest cluster are valid instruments and provide an unbiased estimate even if most other SNPs are invalid [22].
MR-PRESSO	Identifies and removes potentially pleiotropic outliers, but may have high false-positive rate when there are several invalid IVs [24].
Multivariable MR	Extension of univariable MR that estimates the effect of two or more exposures on an outcome, where a secondary exposure can act as a confounder, a mediator, a pleiotropic pathway or a collider [25]. It relies on knowledge of the covariance between the effect of the SNP on each exposure, which is not always available in conventional GWAS results.

IV: instrumental variable; MR: Mendelian randomization; MR-PRESSO: Mendelian Randomization Pleiotropy RESidual Sum and Outlier; SNP: single nucleotide polymorphism.

attainment was associated with lower smoking exposure ($\beta = -0.25$ s.d.; 95% CI: $-0.26, -0.23$) and lower BMI ($\beta = -0.27$ s.d.; 95% CI: $-0.31, -0.24$; i.e. one s.d. increase in education was associated with 1.3 kg/m² lower BMI).

Effect of BMI and smoking behaviour on RA

In univariable MR, each s.d. increase in smoking exposure (OR 2.13; 95% CI: 1.25, 3.62) or in BMI (OR 1.14; 95% CI: 0.95, 1.36) led to a higher relative odds of RA (Fig. 2).

There were bidirectional positive effects between smoking and BMI: smoking exposure increased BMI ($\beta = 0.59$ s.d.; 95% CI: 0.34, 0.84), while BMI increased smoking exposure ($\beta = 0.11$ s.d.; 95% CI: 0.10, 0.13).

Mediation by smoking and BMI behaviour

In the MVMR analysis of education–smoking–RA, the conditional *F*-statistics for educational attainment and smoking exposure were 25 and 8.4, respectively. The direct effect of educational attainment on RA was OR 0.50 (95% CI: 0.42, 0.59) after accounting for smoking (Fig. 2). The direct effect of smoking on RA was OR 2.61 (95% CI: 1.77, 3.84) after accounting for education. The proportion mediated by smoking was 24% (95% CI: 13%, 35%) (Fig. 3).

Conditional *F*-statistics for educational attainment and BMI were 29 and 20, respectively, in the MVMR analysis of education–BMI–RA. The direct effect of educational attainment on RA was OR 0.54 (95% CI: 0.46, 0.63) after accounting for BMI (Fig. 2). After accounting for education, the direct effect of BMI on RA was OR 1.85 (95% CI: 1.53, 2.24). The proportion mediated by BMI was 17% (95% CI: 11%, 23%) (Fig. 3).


When both smoking and BMI were entered into the MVMR model, conditional instrument strength was further reduced (education 18, smoking 5.8, BMI 10). Effect sizes for education (OR 0.59; 95% CI: 0.50, 0.70), BMI (OR 1.60; 95% CI: 1.30, 1.98) and smoking exposure (OR 1.62; 95% CI: 1.03, 2.54) were attenuated (Fig. 2). Combined, BMI and smoking mediated 47% (95% CI: 11%, 82%) of the effect of education on RA (Fig. 3).

Sensitivity analyses

MR sensitivity methods had reduced precision, but generally did not change the causal direction of estimates (Supplementary Tables S3 and S4, Figs S1–S5, available at *Rheumatology* online). There was significant heterogeneity for all MR analyses (Supplementary Table S5), but no evidence of directional pleiotropy (Supplementary Table S6). There was no evidence of reverse causation in reverse MR (Supplementary Table S7), except the recognized bidirectional relationship between BMI and smoking reported above.


Using a smaller education GWAS without UK Biobank, the total effect of education (where one s.d. was 3.6 years of schooling) on RA was similar to the primary analysis (Supplementary Fig. S6, available at *Rheumatology* online). The proportions mediated by smoking (28%; 95% CI: 10%, 46%) and BMI (29%; 95% CI: 8%, 49%) were similar but lacked precision; the estimate for BMI and smoking combined was 45% with CI out of bounds (Supplementary Fig. S7). Restricting to the 10% most strongly associated SNPs for each exposure in the MVMR models of education–smoking (conditional *F* = 48 and 14, respectively) and education–smoking–BMI (*F* = 17; 95% CI: 12, 20) led to point estimates within CIs of the primary analysis, but

Fig. 2 Effect of one s.d. increase in each exposure on odds of RA in uni- and multivariable models



Univariable MR models provide effect estimates for each exposure on the outcome, e.g. each s.d. increase in smoking exposure increases odds of RA by over 2-fold. Multivariable models present estimates adjusting for other factors in the model, e.g. one s.d. increase in educational attainment reduces odds of RA by 50% when accounting for smoking; this effect is attenuated to 41% when adjusting for both smoking and BMI. OR: odds ratio.

Fig. 3 Estimate of the effect of education on RA explained by each mediator and by both combined



PM: proportion mediated.

with reduced precision (Supplementary Fig. S6). Effect estimates were again similar using the weak instrument robust estimator irrespective of covariance (Supplementary Fig. S6). There was no evidence of a total effect of alcohol consumption, physical activity, or dietary composition on RA risk in univariable MR (Supplementary Table S8); therefore mediation was not tested. All SNPs and proxies used are shown in Supplementary Table S9.

Discussion

Genetically predicted higher educational attainment led to lower relative odds of RA (63% lower for every

additional 4.2 years of education). One quarter of this effect was mediated through smoking, and 17% through BMI. In this study, these two leading risk factors for RA accounted for 47% of the total effect of education, suggesting that over half of the effect of education on RA remains unexplained.

This is the first application of MR mediation analysis to study mediators of education and RA risk. The protective effect of higher educational attainment is congruent with findings from traditional observational designs. Each of the following studies also used education as a proxy of wider socioeconomic inequality. Bengtsson *et al.* showed that Swedish patients with university (vs no university) degree had 29% lower relative risk (inverse of the reported relative risk 1.4) of RA [31]. The

effect size was largely unchanged (RR 1.5) when additionally adjusting for smoking status. This small change from unadjusted (total) to adjusted (direct) effects may be explained by the imprecision with which smoking exposure was measured. Pedersen *et al.* showed those with 'long term advanced studies' (formal education >4 years) had lower odds of RA compared with those with no formal education (OR 0.30; 95% CI: 0.18, 0.51); the effect size was reduced (OR 0.43; 95% CI: 0.24, 0.76) after adjusting for smoking, BMI and physical activity [32]. These results are difficult to interpret since years of schooling was also included in models. Both studies were case-control in design with low response rates that differed between the groups—a key source of bias. Neither formally considered a mediation approach to quantify the relative contribution of different risk factors.

Higher educational attainment has been shown to be protective for a range of health outcomes, the effect sizes of which attenuate with adjustment for (i.e. suggestive of mediation by) smoking and BMI [33]. For example, smoking mediated 28% and BMI mediated 18% of education's effect on myocardial infarction [34]. This suggests that public health interventions to reduce smoking and excess adiposity would have widespread benefits on many prevalent comorbidities in RA that drive mortality and additional morbidity.

Our results also suggest that education (and potentially the socioeconomic deprivation that it proxies) may be associated with other important environmental risk factors that increase RA risk. In our analysis, over half of the effect of education remains unaccounted for. Alcohol consumption, physical activity and dietary composition did not appear to have meaningful causal effects on RA risk in our sensitivity analyses. These null results contrast with a host of observational studies that show associations with RA risk, which may reflect unmeasured confounding, measurement error or other biases [35–37]. For example, the allegedly protective properties of alcohol could be due to reverse causation [38]. Null results may also be explained by the difficulty in accurately measuring these exposures in GWASs.

Although educational attainment is commonly used as a proxy for socioeconomic position, it is important to note that they are not interchangeable. Socioeconomic position encapsulates many more factors than education; equally, education may affect health outcomes through mechanisms independent of socioeconomic position. Other measures of socioeconomic position may produce different results from those found here. Genetic instruments for education often do not have a clear biological basis and may instead causally influence related traits closely correlated with education (e.g. other proxies for socioeconomic position).

A key strength of this study is the ability of MR to provide causal estimates. In the context of mediation, MR provides further robustness to non-differential measurement error in the mediator [39]. We used lifetime smoking exposure, which captures dimensions of smoking behaviour overlooked when studying smoking status

[12]. An additional strength of MVMR is that it accommodates the joint effects of multiple mediators even in the presence of bidirectional relationships [9], which was shown for smoking and BMI. There were also limitations. A main source of potential bias in MR studies is horizontal pleiotropy; we examined this using myriad MR methods that provided consistent results to the main analysis. We were not able to examine potential for exposure-mediator interaction; estimates would be biased if smoking behaviour interacts with causal effect of education on RA risk. The current analysis assumes a linear effect of education on each outcome; it is nevertheless a valid test of the causal null hypothesis even should this assumption not hold [40]. Prior observational studies of deprivation and education showed a particularly strong association with seropositive RA [32]; we were not able to examine serostatus in the current study. Inferences drawn from our results apply to RA onset, and may not be extrapolatable to RA prognosis (indeed, MR studies of disease progression may be subject to additional biases [41]). Instrumental variable methods (including MR) estimate the 'local average treatment effects' not population average effects; here it is the average effect of education for individuals whose educational attainment was increased by the SNPs (i.e. a subgroup). This further requires the direction of SNP effects on education, and indeed the SNP effects on each mediator, to be in the same direction for all individuals ('monotonicity'). Neither the subgroup proportion nor monotonicity can be empirically verified. MR is less susceptible to confounding than other observational designs (as genetic variants are predetermined) but not immune; one potential confounder which can occur at a sample level is population stratification (i.e. correlation arising from sub-populations with different distributions of both genetic variants and the exposure/outcome) [42, 43]. This would be interesting to investigate in future studies using within-family data. GWA studies providing summary statistics for this analysis were limited to those of European descent and each attempted to adjust for population structure, e.g. using principal components. Lastly, MR may not capture time-varying nature of the exposures; a snapshot BMI measurement may not fully represent BMI over the life course [44]. This is particularly relevant to genetic instruments for physical activity, diet and alcohol intake, which we considered in sensitivity analyses.

In conclusion, we showed a protective effect of higher educational attainment on RA risk; interventions to reduce smoking and excess adiposity at a population level may reduce much of this risk. This is particularly relevant for those with high risk of developing RA (e.g. those with strong family history). However, the majority of education's effect on RA remain unexplained. Broader efforts to improve socioeconomic inequalities and access to education are required, as well as further research into other environmental risk factors that act as potentially modifiable mediators of socioeconomic deprivation.

Acknowledgements

E.S. and A.R.C. work in a unit that receives core funding from the UK Medical Research Council and University of Bristol (MC_UU_00011/1 and MC_UU_00011/6). M.V.H. works in a unit that receives funding from the UK Medical Research Council and is supported by a British Heart Foundation Intermediate Clinical Research Fellowship (FS/18/23/33512) and the National Institute for Health Research Oxford Biomedical Research Centre. J.Z. is supported by the UK Medical Research Council Integrative Epidemiology Unit (MC_UU_00011/1 and MC_UU_00011/4), the Academy of Medical Sciences (AMS) Springboard Award, the Wellcome Trust, the Government Department of Business, Energy and Industrial Strategy (BEIS), the British Heart Foundation and Diabetes UK (SBF006\1117), and is funded by the Vice-Chancellor Fellowship from the University of Bristol. S.S.Z. analysed the data and wrote the manuscript with significant input from all co-authors.

Ethics: Participating studies of respective GWAS meta-analyses have received prior approval by relevant institutional review boards, and informed consent was obtained from each study participant (references in Table 1). The current study used publicly available summary statistics data, and thus no additional ethics approval was required.

Funding: No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.

Disclosure statement: The authors have declared no conflicts of interest.

Data availability statement

Summary statistics are available from each consortium (details in Table 1) or via the MR-Base platform (<https://gwas.mrcieu.ac.uk/>).

Supplementary data

Supplementary data are available at *Rheumatology* online.

References

- Calixto O-J, Anaya J-M. Socioeconomic status. The relationship with health and autoimmune diseases. *Autoimmun Rev* 2014;13:641–54.
- Verstappen SMM. The impact of socio-economic status in rheumatoid arthritis. *Rheumatology (Oxford)* 2017;56:1051–2.
- Doeglas D, Suurmeijer T, Krol B *et al.* Work disability in early rheumatoid arthritis. *Ann Rheum Dis* 1995;54:455–60.
- Galobardes B, Shaw M, Lawlor DA, Lynch JW, Davey Smith G. Indicators of socioeconomic position (part 1). *J Epidemiol Community Health* 2006;60:7–12.
- Qian Y, Zhang L, Wu DJH *et al.* Genetic predisposition to smoking is associated with risk of rheumatoid arthritis: a Mendelian randomization study. *Arthritis Res Ther* 2020;22:44.
- Tang B, Shi H, Alfredsson L *et al.* Obesity-related traits and the development of rheumatoid arthritis – evidence from genetic data. *Arthritis Rheumatol* 2021;73:203–11.
- Davies NM, Holmes MV, Smith GD. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ* 2018;362:k601.
- Zhao SS, Mackie SL, Zheng J. Why clinicians should know about Mendelian randomization. *Rheumatology (Oxford)* 2021;60:1577–9.
- Carter AR, Sanderson E, Hammerton G *et al.* Mendelian randomisation for mediation analysis: current methods and challenges for implementation. *Eur J Epidemiol* 2021;36:465–78.
- Lee JJ, Wedow R, Okbay A *et al.*; Social Science Genetic Association Consortium. Gene discovery and polygenic prediction from a 1.1-million-person GWAS of educational attainment. *Nat Genet* 2018;50:1112–21.
- Yengo L, Sidorenko J, Kemper KE *et al.*; GIANT Consortium. Meta-analysis of genome-wide association studies for height and body mass index in ~700000 individuals of European ancestry. *Hum Mol Genet* 2018;27:3641–9.
- Wootton RE, Richmond RC, Stuijzand BG *et al.* Evidence for causal effects of lifetime smoking on risk for depression and schizophrenia: a Mendelian randomisation study. *Psychol Med* 2020;50:2435–43.
- Okada Y, Wu D, Trynka G *et al.*; GARNET consortium. Genetics of rheumatoid arthritis contributes to biology and drug discovery. *Nature* 2014;506:376–81.
- Okbay A, Beauchamp JP, Fontana MA *et al.*; LifeLines Cohort Study. Genome-wide association study identifies 74 loci associated with educational attainment. *Nature* 2016;533:539–42.
- Liu M, Jiang Y, Wedow R *et al.*; HUNT All-In Psychiatry. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. *Nat Genet* 2019;51:237–44.
- Trait: Duration of vigorous activity – IEU OpenGWAS project. 2021. <https://gwas.mrcieu.ac.uk/datasets/ukb-b-13932/> (1 December 2020, date last accessed).
- Meddens SFW, R de V, Bowers P *et al.* Genomic analysis of diet composition finds novel loci and associations with health and lifestyle. *Mol Psychiatry* (in press), doi: 10.1038/s41380-020-0697-5.
- Burgess S, Labrecque JA. Mendelian randomization with a binary exposure variable: interpretation and presentation of causal estimates. *Eur J Epidemiol* 2018;33:947–52.
- Burgess S, Thompson SG; CRP CHD Genetics Collaboration. Avoiding bias from weak instruments in Mendelian randomization studies. *Int J Epidemiol* 2011;40:755–64.

- 20 Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol* 2013;37: 658–65.
- 21 Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. *Genet Epidemiol* 2016;40:304–14.
- 22 Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol* 2017;46:1985–98.
- 23 Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol* 2015;44:512–25.
- 24 Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet* 2018;50:693–8.
- 25 Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. *Int J Epidemiol* 2019;48:713–27.
- 26 Hemani G, Tilling K, Smith GD. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. *PLoS Genet* 2017;13:e1007081.
- 27 Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample Mendelian randomization. *Genet Epidemiol* 2016;40:597–608.
- 28 Sanderson E, Spiller W, Bowden J. Testing and correcting for weak and pleiotropic instruments in two-sample multivariable Mendelian randomisation. *Stat Med* 2021; doi: 10.1002/sim.9133.
- 29 Smolen JS, Aletaha D, Barton A *et al.* Rheumatoid arthritis. *Nat Rev Dis Primers* 2018;4:18001.
- 30 Walker VM, Davies NM, Hemani G *et al.* Using the MR-Base platform to investigate risk factors and drug targets for thousands of phenotypes. *Wellcome Open Res* 2019; 4:113.
- 31 Bengtsson C, Nordmark B, Klareskog L, Lundberg I, Alfredsson L; EIRA Study Group. Socioeconomic status and the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. *Ann Rheum Dis* 2005;64: 1588–94.
- 32 Pedersen M, Jacobsen S, Klarlund M, Frisch M. Socioeconomic status and risk of rheumatoid arthritis: a Danish case-control study. *J Rheumatol* 2006;33: 1069–74.
- 33 Yuan S, Xiong Y, Michaëlsson M, Michaëlsson K, Larsson SC. Health-related effects of education level: a Mendelian randomization study. *medRxiv*, doi: 10.1101/2020.02.01.20020008, 13 September 2020, preprint: not peer reviewed.
- 34 Carter AR, Gill D, Davies NM *et al.* Understanding the consequences of education inequality on cardiovascular disease: Mendelian randomisation study. *BMJ* 2019;365: l1855.
- 35 Liu X, Tedeschi SK, Lu B *et al.* Long-term physical activity and subsequent risk for rheumatoid arthritis among women: a prospective cohort study. *Arthritis Rheumatol* 2019;71:1460–71.
- 36 Giuseppe DD, Alfredsson L, Bottai M, Askling J, Wolk A. Long term alcohol intake and risk of rheumatoid arthritis in women: a population based cohort study. *BMJ* 2012; 345:e4230.
- 37 Cutolo M, Nikiphorou E. Don't neglect nutrition in rheumatoid arthritis! *RMD Open* 2018;4:e000591.
- 38 Baker JF, England BR, Mikuls TR *et al.* Changes in alcohol use and associations with disease activity, health status, and mortality in rheumatoid arthritis. *Arthritis Care Res* 2020;72:301–8.
- 39 Carter AR, Sanderson E, Hammerton G *et al.* Mendelian randomisation for mediation analysis: current methods and challenges for implementation. *Eur J Epidemiol* 2021;36:465–78.
- 40 Burgess S, Davies NM, Thompson SG; EPIC-InterAct Consortium. Instrumental variable analysis with a nonlinear exposure-outcome relationship. *Epidemiology* 2014;25:877–85.
- 41 Paternoster L, Tilling K, Smith DG. Genetic epidemiology and Mendelian randomization for informing disease therapeutics: conceptual and methodological challenges. *PLoS Genet* 2017;13:e1006944.
- 42 Sanderson E, Richardson TG, Hemani G, Davey Smith G. The use of negative control outcomes in Mendelian randomization to detect potential population stratification. *Int J Epidemiol* 2021 (in press), doi: 10.1093/ije/dyaa288.
- 43 Brumpton B, Sanderson E, Heilbron K *et al.*; 23andMe Research Team. Avoiding dynastic, assortative mating, and population stratification biases in Mendelian randomization through within-family analyses. *Nat Commun* 2020;11:3519.
- 44 Labrecque JA, Swanson SA. Commentary: Mendelian randomization with multiple exposures: the importance of thinking about time. *Int J Epidemiol* 2020; 49:1158–62.

A 2nd generation, JAK1 preferential inhibitor for moderate to severe RA¹⁻⁶

While 1st generation JAK inhibitors are relatively non-selective,²⁻⁶ JYSELECA has over 5x greater potency for JAK1 over JAK2/3 and TYK2^{1*}

Balancing sustained efficacy⁷⁻¹¹ with acceptable tolerability^{1,12}

Indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs.¹ May be used as monotherapy or in combination with methotrexate.¹

*From biochemical assays, the clinical relevance of which is uncertain. JAK, Janus kinase; RA, rheumatoid arthritis; TYK, tyrosine kinase.

Learn more at
strengthofbalance.co.uk

Refer to Summary of Product Characteristics (SmPC) before prescribing, and for full prescribing information.

JYSELECA ▽ filgotinib 100 mg or 200 mg film-coated tablets.

Indication: Jyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs). Jyseleca may be used as monotherapy or in combination with methotrexate (MTX). **Dosage:** Adults: 200 mg once daily. Taken orally with/without food. It is recommended that tablets are swallowed whole. **Laboratory Monitoring:** Refer to the SmPC for information regarding laboratory monitoring and dose initiation or interruption. **Elderly:** A starting dose of 100 mg once daily is recommended for patients aged 75 years and older as clinical experience is limited. **Renal impairment:** No dose adjustment required in patients with estimated creatinine clearance (CrCl) ≥ 60 mL/min. A dose of 100 mg of filgotinib once daily is recommended for patients with moderate or severe renal impairment (CrCl 15 to < 60 mL/min). Not recommended in patients with CrCl < 15 mL/min. **Hepatic impairment:** Mild/moderate hepatic impairment: no dose adjustment required. Severe hepatic impairment: not recommended. **Children (< 18 years):** Safety and efficacy not yet established. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients. Active tuberculosis (TB) or active serious infections. **Pregnancy/Precautions:** See SmPC for full information. **Immunosuppression:** Combination use, with immunosuppressants e.g., ciclosporin, tacrolimus, biologics or other Janus kinase (JAK) inhibitors is not recommended as a risk of additive immunosuppression cannot be excluded. **Infections:** Infections, including serious infections such as pneumonia and opportunistic infections e.g. tuberculosis (TB), oesophageal candidiasis, and cryptococcosis have been reported. Risk benefit should be assessed prior to initiating in patients with risk factors for infections (see SmPC). Patients should be closely monitored for the development of signs and symptoms of infections during and after filgotinib treatment. Treatment should be interrupted if the patient

is not responding to antimicrobial therapy, until infection is controlled. There is a higher incidence of serious infections in the elderly aged 75 years and older, caution should be used when treating this population. **Tuberculosis:** Patients should be screened for TB before initiating filgotinib, and filgotinib should not be administered to patients with active TB. **Viral reactivation:** Cases of herpes virus reactivation (e.g., herpes zoster) were reported in clinical studies (see SmPC). If a patient develops herpes zoster, filgotinib treatment should be temporarily interrupted until the episode resolves. Screening for viral hepatitis and monitoring for reactivation should be performed. **Malignancy:** Immunomodulatory medicinal products may increase the risk of malignancies. Malignancies were observed in clinical studies (see SmPC). **Fertility:** In animal studies, decreased fertility, impaired spermatogenesis, and histopathological effects on male reproductive organs were observed (see SmPC). The potential effect of filgotinib on sperm production and male fertility in humans is currently unknown. **Haematological abnormalities:** Do not start therapy, or temporarily stop, if Absolute Neutrophil Count (ANC) < 1 × 10⁹ cells/L, ALC < 0.5 × 10⁹ cells/L or haemoglobin < 8 g/dL. Temporarily stop therapy if these values are observed during routine patient management. **Vaccinations:** Use of live vaccines during, or immediately prior to, filgotinib treatment is not recommended. **Lipids:** Treatment with filgotinib was associated with dose dependent increases in lipid parameters, including total cholesterol, and high-density lipoprotein (HDL) levels, while low density lipoprotein (LDL) levels were slightly increased (see SmPC). **Cardiovascular risk:** Rheumatoid arthritis patients have an increased risk for cardiovascular disorders. Patients should have risk factors (e.g., hypertension, hyperlipidaemia) managed as part of usual standard of care. **Venous thromboembolism:** Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients receiving JAK inhibitors including filgotinib. Caution should be used in patients with risk factors for DVT/PE, such as older age, obesity, a medical history of DVT/PE, or patients undergoing surgery, and prolonged

immobilisation. **Lactose content:** Contains lactose; patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take filgotinib. **Pregnancy/Lactation:** Filgotinib is contraindicated in pregnancy. Filgotinib should not be used during breast-feeding. Women of childbearing potential must use effective contraception during and for at least 1 week after cessation of treatment. **Driving/Using machinery:** No or negligible influence, however dizziness has been reported. **Side effects:** See SmPC for full information. **Common** (≥1/100 to <1/10): nausea, upper respiratory tract infection, urinary tract infection and dizziness. **Uncommon** (≥1/1000 to <1/100): herpes zoster, pneumonia, neutropenia, hypercholesterolaemia and blood creatine phosphokinase increase. **Serious side effects:** See SmPC for full information. **Legal category:** POM. **Pack:** 30 film-coated tablets/bottle. **Price:** UK Basic NHS cost: £863.10. **Marketing authorisation number(s):** Great Britain Jyseleca 100mg film-coated tablets PLGB 42147/0001 Jyseleca 200mg film-coated tablets PLGB 42147/0002 Northern Ireland Jyseleca 100mg film-coated tablets EU/1/20/1480/001 EU/1/20/1480/002 Jyseleca 200mg film-coated tablets EU/1/20/1480/003 EU/1/20/1480/004 **Further information:** Galapagos UK, Belmont House, 148 Belmont Road, Uxbridge UB8 1QS, United Kingdom 00800 7878 1345 medicalinfo@gpg.com Jyseleca® is a trademark. **Date of Preparation:** January 2022 UK-RA-FIL-202201-00019

▽ Additional monitoring required

Adverse events should be reported.

For Great Britain and Northern Ireland, reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (download from the Apple App Store or Google Play Store).

Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@gpg.com or 00800 7878 1345

References: 1. JYSELECA SPC. Available at: www.medicines.org.uk. Last accessed: June 2022. 2. Angelini J, et al. Biomolecules 2020;10(7):E1002. 3. Banerjee S, et al. Drugs 2017;77:521-546. 4. O'Shea JJ, et al. Nat Rev Rheumatol 2013;9(3):173-182. 5. Traves PG, et al. Ann Rheum Dis 2021;04:11. 6. McInnes IB, et al. Arthr Res Ther 2019;21:183. 7. Combe B, et al. Ann Rheum Dis 2021;doi:10.1136/annrheumdis-2020-219214. 8. Genovese MC, et al. JAMA 2019;322 (4):315-325. 9. Westhovens R, et al. Ann Rheum Dis 2021;doi:10.1136/annrheumdis-2020-219213. 10. Combe B, et al. Arthritis Rheumatol 2021;73(suppl. 10). <https://acrabstracts.org/abstract/clinical-outcomes-up-to-week-48-of-filgotinib-treatment-in-an-ongoing-long-term-extension-trial-of-ra-patients-with-inadequate-response-to-mtx-initially-treated-with-filgotinib-or-adalimumab-during-th/>. Last accessed: June 2022. 11. Buch MH, et al. Arthritis Rheumatol 2021;73 (suppl. 10). <https://acrabstracts.org/abstract/clinical-outcomes-up-to-week-48-of-ongoing-filgotinib-ra-long-term-extension-trial-of-biologic-dmard-inadequate-responders-initially-on-filgotinib-or-placebo-in-a-phase-3-trial/>. Last accessed: June 2022. 12. Winthrop K, et al. Arthritis Rheumatol 2021;73(suppl. 10). Available at: <https://acrabstracts.org/abstract/integrated-safety-analysis-update-for-filgotinib-in-patients-with-moderately-to-severely-active-rheumatoid-arthritis-receiving-treatment-over-a-median-of-2-2-years/>. Last accessed: June 2022.

Galápagos

June 2022 GB-RA-JY-202205-00033

JYSELECA, GALAPAGOS and the JYSELECA and GALAPAGOS logos are registered trademarks of Galapagos NV. © 2022 Galapagos NV. All rights reserved.